BALAXI · Healthcare · Drug Manufacturers - Specialty & Generic
| Share price | ₹24.39 |
| Market cap | ₹135 Cr |
| P/E ratio | 93.8 |
| P/B ratio | 0.5 |
| ROE | 12.9% |
| ROCE | 3.3% |
| Book value | ₹44.71 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹270 Cr | ₹1 Cr | 2.4% |
| 2025 | ₹293 Cr | ₹25 Cr | 12.1% |
| 2024 | ₹241 Cr | ₹-2 Cr | 19.0% |
| 2023 | ₹336 Cr | ₹46 Cr | 16.5% |
| 2022 | — | — | — |
Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in India, Africa, and Latin America. The company offers pharmaceutical products across various therapeutic areas, including antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpaste. The company was formerly known as Balaxi Ventures Limited and changed its name to Balaxi Pharmaceuticals Limited in October 2020. The company was incorporated in 1942 and is headquartered in Hyderabad, India. Balaxi Pharmaceuticals Limited is a